Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CEO Emily Leproust sold 655 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $200.00, for a total value of $131,000.00. Following the completion of the transaction, the chief executive officer owned 613,044 shares of the company’s stock, valued at $122,608,800. The trade was a 0.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Twist Bioscience Price Performance
NASDAQ:TWST opened at $155.65 on Thursday. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $219.71. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $9.76 billion, a P/E ratio of -70.11 and a beta of 2.19. The stock’s fifty day moving average is $141.74 and its two-hundred day moving average is $95.17.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The business had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.33 earnings per share. Equities analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.
Analysts Set New Price Targets
View Our Latest Analysis on TWST
Institutional Investors Weigh In On Twist Bioscience
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Western Wealth Management LLC acquired a new position in shares of Twist Bioscience during the first quarter worth $31,000. Strs Ohio acquired a new stake in Twist Bioscience in the first quarter valued at $33,000. Strategic Advocates LLC raised its stake in Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after buying an additional 906 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after buying an additional 453 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new position in shares of Twist Bioscience during the 1st quarter worth about $54,000.
Twist Bioscience News Summary
Here are the key news stories impacting Twist Bioscience this week:
- Positive Sentiment: Recent business momentum remains intact: Twist’s latest quarterly update included record revenue of $118.4 million, revenue growth of 23% year over year, gross margin above 52%, and higher full-year revenue guidance. Revenue also exceeded analyst expectations, although the company remained loss-making.
- Positive Sentiment: Lilly collaboration initially boosted enthusiasm: News of the Lilly TuneLab partnership helped drive a substantial rally, reflecting investor interest in Twist’s synthetic-DNA platform and potential drug-discovery applications. However, the durability and strategic value of the collaboration are now being debated.
- Positive Sentiment: Some analysts remain constructive: Guggenheim reportedly raised its price target to $212 and maintained a buy rating, while broader analyst coverage still reflects a “Moderate Buy” consensus. Twist Bioscience stock gained after Lilly deal
- Neutral Sentiment: Insider transactions were largely prearranged: CEO Emily Leproust sold shares under a Rule 10b5-1 plan, including stock used for tax withholding, while other executives also reported sales. These transactions do not necessarily indicate discretionary bearish views, but the concentration of selling has attracted investor attention. SEC insider transaction filing
- Negative Sentiment: Insider selling and valuation pressure: Recent filings showed sales by Leproust and other insiders, while reported insider activity over the past six months contained sales but no purchases. With TWST trading far above many older analyst targets and still posting losses, the filings encouraged profit-taking after the stock’s major run-up.
- Negative Sentiment: Partnership skepticism and dilution concerns: Analysts questioning the eventual strategic payoff from the Lilly deal weakened the bullish narrative. Investors are also mindful of Twist’s $300 million August stock offering, which increased potential dilution.
Twist Bioscience Company Profile
Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.
The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.
Featured Articles
- Five stocks we like better than Twist Bioscience
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
